121 |
JPS50108221A - |
JP1264775 |
1975-01-31 |
JPS50108221A |
1975-08-26 |
|
|
122 |
JPS4994828A - |
JP13745473 |
1973-12-11 |
JPS4994828A |
1974-09-09 |
|
|
123 |
JPS4949941A - |
JP6822473 |
1973-06-16 |
JPS4949941A |
1974-05-15 |
|
|
124 |
Method for producing a polyisocyanate composition |
JP2001148247 |
2001-05-17 |
JP4849736B2 |
2012-01-11 |
佳司郎 原田; 慎一郎 渡邊; 邦夫 直井 |
|
125 |
Synthesis of acyloxyalkyl derivative of Gaba analogues |
JP2004511254 |
2003-06-11 |
JP4310271B2 |
2009-08-05 |
マーク エイ ギャロップ; ジア ニン シャン; シンディー エックス ツォウ; サレッシュ クーマー マンサティ; フェンメイ ヤオ; スティーブン ピー レイラード |
|
126 |
Dimethyl-(3-aryl-but-3-enyl)-amino compound as pharmaceutical active ingredient |
JP2008066934 |
2008-03-17 |
JP2008273937A |
2008-11-13 |
BUSCHMANN HELMUT HEINRICH; STRASSBURGER WOLFGANG WERNER A; FRIDERICHS ELMAR JOSEF DR; KOEGEL BABETTE-YVONNE DR |
PROBLEM TO BE SOLVED: To obtain a dimethyl-(3-aryl-but-3-enyl)-amino compound and to provide a method for producing the same and a method for using the compound as a pharmaceutical.
SOLUTION: The dimethyl-(3-aryl-but-3-enyl)-amino compound is represented by formula 1.
COPYRIGHT: (C)2009,JPO&INPIT |
127 |
Regulation of anxiety by blocking anandamide hydrolysis |
JP2004543510 |
2003-10-07 |
JP2006511484A |
2006-04-06 |
ジョージオ タージア; アンドレア デュランティ; アンドレア トンティニ; ダニエル ピオメリ; マルコ モール |
式(I)の脂肪酸アミドヒドロラーゼ阻害剤が提供され、ここで、XはNH、CH
2 、O、またはSであり; QはOまたはSであり; ZはOまたはNであり; Rは、置換または非置換アリール; 置換または非置換ビフェニリル、置換または非置換ナフチル、および置換または非置換フェニル; 置換または非置換テルフェニリル; 置換または非置換シクロアルキル、ヘテロアリール、またはアルキルからなる群より選択される芳香族部分であり; ならびにR
1およびR
2は独立して、ZがOであるならばR
1およびR
2の一方がないという条件で、H、置換または非置換アルキル、置換または非置換ヘテロアルキル、および置換または非置換フェニル、置換または非置換ビフェニリル、置換または非置換アリール、および置換または非置換ヘテロアリールからなる群より選択され、およびZがNであるならという条件で、R
1およびR
2は任意で共に、これらが各々結合するN原子と置換もしくは非置換N-複素環または置換もしくは非置換ヘテロアリールを形成してもよい。 式(I)の化合物を含有する薬学的組成物、ならびにFAAHを阻害するためのおよび/または食欲障害、緑内障、疼痛、不眠症、ならびに不安障害、てんかん、および抑うつを含む神経障害および心理的障害を処置するためのその組成物の使用方法が提供される。
|
128 |
Prodrug of Gaba analogues, its composition and use |
JP2004559321 |
2003-12-05 |
JP2006509031A |
2006-03-16 |
イアン アール オールマン; ケニス シー カンディー; ファヤン ジー キウ; マーク エイ ギャロップ; ジア ニン シアン; シンディー エックス ゾー; フェンメイ ヤオ |
本発明は、GABA類似体のプロドラッグ、GABA類似体のプロドラッグの医薬組成物及びGABA類似体のプロドラッグの製造方法を提供する。 本発明は、GABA類似体のプロドラッグの使用方法並びに普通の病気及び/又は障害を治療又は予防するためのGABA類似体のプロドラッグの医薬組成物の使用方法をも提供する。 |
129 |
Aldehydes, solid phase synthesis of a ketone, oxime, amine and hydroxamic acid compounds |
JP53023198 |
1997-12-17 |
JP2001512419A |
2001-08-21 |
ジョセフ エム サルヴィノ; ヘレン ジェイ メーソン; ジョージ シー モートン; リチャード エフ ラボーダイニアー |
(57)【要約】 本発明はアルデヒド、ケトン、オキシム、アミン及びヒドロキサム酸化合物の固相合成方法並びにそれらに有益なポリマーヒドロキシルアミン樹脂化合物に関する。 |
130 |
Adhesion promoter |
JP15499590 |
1990-06-13 |
JP2873721B2 |
1999-03-24 |
JOBANNI PARINERO; FUBERUTO SHIMON; RORUFU MYUURUHAUPUTO |
Compounds of general formula I I wherein R2 is hydrogen unsubstituted C1-C6alkyl or C1-C6alkyl substituted by -OH, -CN or by -Si(OR3)3-qR4q, or C2-C6alkenyl, R3 is C1-C4alkyl, or two radicals R3 together are C1-C4alkylene, R4 is C1-C4alkyl or phenyl, and q is from 0 to 2, and E is a radical of the formula wherein R5 is hydrogen or C1-C4alkyl and R6is hydrogen, or R5 and R6 together are C4-C8alkylene, or and A is -(CH2)r-O-, wherein r is 1,2 or 3, and p is 0 or 1, and Y is oxygen or sulfur; and wherein T is a radical -R9-Si(OR3)3-qR4q, a radical of the formula X is -S- or -NH-, and Z is an organic radical derived from a polyisocyanate or polyisothiocyanate having at least 2 NCO or NCS groups, respectively, are suitable as adhesion promoters, especially for moisture-curing polyurethane resins. |
131 |
Microanalysis method for carbamate compound |
JP18135697 |
1997-07-07 |
JPH1123548A |
1999-01-29 |
SAKUMA HISAKO; TAKAHASHI RYUJI; YAMADA TSUYOSHI; SUZUKI HIROSHI |
PROBLEM TO BE SOLVED: To quickly make the microanalysis measurement of a trace carbamate compound by using an eluant removed with a foreign matter using a filter. SOLUTION: An eluant 6 is fed to an analysis line by a pump 5, and a filter is provided on an analysis passage system to remove a foreign matter. A sample is injected from an injector 2, and components are fractionally eluted in a separation column 3 kept at the prescribed temperature by an oven 9. An alkaline aqueous solution 7 is fed to the eluant 6 by a pump 5 through the passage system, and a carbamate compound is decomposed by alkali in a reaction pipe coil 11. A fluorescent derivative reagent 8 is fed to the eluant 6 flowing from the reaction pipe coil 11 by the pump 5 through the passage system, the reagent 8 is reacted with the first-grade amine generated by the decomposed carbamate compound in a reaction pipe coil 12 held in the prescribed temperature in the oven to generate a fluorescent derivative compound, and it is quantitatively analyzed by a fluorescence detector 4. The carbamate compound can be quickly measured with high sensitivity. |
132 |
Anticonvulsant or for nerve protection for pharmaceutical |
JP20706289 |
1989-08-11 |
JP2846895B2 |
1999-01-13 |
JEIMUZU JEI NEEPIA; RONARUDO SHII GURIFUISU |
|
133 |
The preparation of N- hydroxy carbamate |
JP31712592 |
1992-11-26 |
JP2798164B2 |
1998-09-17 |
克彦 水垂; 秀二 田中; 圭吾 西平; 正宏 近藤 |
|
134 |
Inhibitor compound of phosphodiesterase iv and method of inhibiting |
JP50350696 |
1995-06-23 |
JPH10502354A |
1998-03-03 |
カバラ,デイヴィッド; チェイシン,マーク; ドルビー,ロイド; ダブリュ. フリス,リチャード |
(57)【要約】 有効なPDE IV阻害剤である新規化合物を記載する。 該化合物は、ロリプラム(rolipram)と比べて同程度のまたは向上したPDE IV阻害作用を示し、例えばPDE III阻害に関して、向上した選択性を有する。 好ましい化合物は、3-(3- シクロペンチルオキシ-4- メトキシベンジルアミノ)-4-ヒドロキシメチルピラゾールおよび3-(3- シクロペンチルオキシ-4- メトキシベンジルアミノ)-4-メトキシメチルピラゾールである。 |
135 |
Systematic module production of molecules based on amine imide and oxazolone having at least two structural diversity elements |
JP53040795 |
1995-05-18 |
JPH10500685A |
1998-01-20 |
シー.ジュニア ホーガン,ジョセフ |
(57)【要約】 少なくとも2つの構造多様性要素を有する、アミンイミドおよびオキサゾロンをベースとした分子およびそのアレイが系統的モジュール製造により形成される。 アミンイミドおよびオキサゾロンをベースとした分子のコンビナトリアルライブラリーが系統的モジュール製造により作製される。 |
136 |
Dimethyl-(3-aryl-buto-3-enyl)-amino compound as pharmaceutically active substance |
JP5769597 |
1997-03-12 |
JPH107624A |
1998-01-13 |
BUSCHMANN HELMUT HEINRICH; STRASBURGER WOLFGANG WERNER A; FRIDERICHS ELMAR JOSEF DR; KOEGEL BABETTE-YVONNE DR |
PROBLEM TO BE SOLVED: To obtain the subject new compound having excellent analgesic action, free from adverse effects of sickness, vomiting, etc., not exhibiting adverse effects which opioid have and useful as a therapeutic agent for strong pain. SOLUTION: An antipode or a racemic modification of a compound (salt) represented by formula I [R<1> is a 1-5C alkyl; R<2> is H or R<1> or R<1> and R<2> together form (CH2 )2-4 , etc.; R<3> is H or R<1> ; R<4> and R<6> are each H, OH, a 1-4C alkyl(oxy), etc.; R<5> is R<4> or CHF2 ; in R<4> to R<6> , two groups among R<4> to R<6> are each H or R<4> and R<5> together form a group of the formula CH=C(R<9> )-O (R<9> is H or a 1-4C alkyl), a group of the formula CH=C(R<9> )-S, etc.], e.g. (Z)-(RS)-[3-(3-methoxy-phenyl)-2-methyl-pento-3-enyl]-dimethylamine hydrochloride. The compound of formula I is obtained by reacting a compound of formula II with a compound of formula III (Z is MgCl, MgBr, MgI or Li) to afford a compound of formula IV and dehydrating the compond of formula IV. |
137 |
Curable composition for coating |
JP26642096 |
1996-10-07 |
JPH09169839A |
1997-06-30 |
BURAIAN DEII BAMERU; JIYON DEII MAGII; UORUTAA EICHI OUBOMU; TOTSUDO EI SHIIBAA; GUREGORII JII MENOBUCHITSUKU; POORU JIEI HARISU; JIYON DABURIYU REIFUYUSU |
PROBLEM TO BE SOLVED: To obtain a coating compsn. having a combination of excellent properties, such as durability, hardness, and resistance to scratch, marring, solvents, and acids.
SOLUTION: A compd. (A) contg. a carbamate or urea group or a group convertible to carbamate or urea and an active hydrogen group capable of reacting with a hydroxycarboxylic acid or capable of reacting with a lactone in a ring opening reaction is reacted with a lactone or a hydroxycarboxylic acid to prepare a urea carbamate or functional-, functional ester- or amide-contg. compd. The compd. thus prepd. is useful in a curable compsn. This compsn. comprises a curing agent contg. a plurality of groups reactive with the functional group on the compd. (A).
COPYRIGHT: (C)1997,JPO |
138 |
A fact that is tritiated 16-imino-17-aza manufacturing intermediate member of the steroid |
JP23447294 |
1994-09-05 |
JP2512388B2 |
1996-07-03 |
ARAN JUKEI; PIITAA FURANSHISU HANTO |
|
139 |
Intermediate for preparing tritiated 16-imino-17-aza-steroid |
JP23447494 |
1994-09-05 |
JPH07324065A |
1995-12-12 |
ARAN JIYUKEI; PIITAA FURANSHISU HANTO |
PURPOSE: To obtain the subject compound having a specific formula, useful as an intermediate for preparing an aza-steroid or a radioactively labelled GABAreceptor substance.
CONSTITUTION: This intermediate is expressed by formula I (A is H or tritium; R is a 1-8C acyl) and is obtained by using a compound of formula II or the like, concretely 3α-acetoxy-11,17-dioxo-5β-androstane or the like as a starting material, and treating it with an oximation agent, then with an acid chloride- forming agent and ammonia, and then treating with a hypohalogenous acid salt of MOX (M is an alkali metal) in the presence of a base.
COPYRIGHT: (C)1995,JPO |
140 |
Intermediate for preparing tritiated 16-imino-17-aza-steroid |
JP23447394 |
1994-09-05 |
JPH07324064A |
1995-12-12 |
ARAN JIYUKEI; PIITAA FURANSHISU HANTO |
PURPOSE: To obtain the subject compound having a specific formula, useful as an intermediate for preparing an aza-steroid or a radioactively labelled GABA-receptor substance.
CONSTITUTION: This intermediate is expressed by formula I (A is H or tritium; R is a 1-8C acyl) and is obtained by using a compound of formula II or the like, concretely 3α-acetoxy-11,17-dioxo-5β-androstane or the like, as a starting material, and treating it with an oximation agent and then with an acid chloride-forming agent, and further with ammonia.
COPYRIGHT: (C)1995,JPO |